Treatment of refractory juvenile idiopathic arthritis via pulse therapy using methylprednisolone and cyclophosphamide
Keywords:
Rheumatoid athritis, Juvenile rheumatoid arthritis, Arthritis, Methylprednisolone, Cyclophosphamide, MethotrexateAbstract
CONTEXT: Patients with refractory juvenile idiopathic arthritis can benefit from aggressive therapy. CASE REPORT: We followed the clinical course of 4 patients (2 male, 2 female) aged 9.1-17.8 years (mean of 14.5 years) with polyarticular onset of juvenile rheumatoid arthritis and one 16-year old boy with juvenile spondyloarthropathy associated with inflammatory bowel disease. All the juvenile rheumatoid arthritis patients fulfilled the diagnostic criteria established by the American College of Rheumatology. All patients had unremitting arthritis despite maximum therapy. All patients began receiving treatment using intravenous cyclophosphamide at 500-750 mg/m2 and intravenous methylprednisolone at 30 mg/ kg, for 3 days monthly (1 g maximum). The patients received between 3 and 11 monthly treatments, and/or 3-5 treatments every two months for 12 months, according to the severity of the disease and/or response to the therapy. All but one patient were evaluated retrospectively at the start (time 0) and 6 months (time 1), and 12 months (time 2) after the beginning of the treatment. A rapid and clinically significant suppression of systemic and articular manifestations was seen in all patients. Our results showed the favorable effect of this treatment on the clinical and some laboratory manifestations of juvenile idiopathic arthritis.
Downloads
References
Criteria for the classification of juvenile rheumatoid arthritis. Bull Rheum Dis 1972;23(5):712-9.
DeSilva TN, Kress DW. Management of collagen vascular dis- eases in childhood. Dermatol Clin 1998;16(3):579-92.
Schaller JG. Aggressive treatment in childhood rheumatic dis- eases. Clin Exp Rheumatol 1994;12(Suppl 10):S97-105.
Lehman TJ. Aggressive therapy for childhood rheumatic dis- eases. When are immunosuppressives appropriate? Arthritis Rheum 1993;36(1):71-4.
Singsen BH, Goldbach-Mansky R. Methotrexate in the treat- ment of juvenile rheumatoid arthritis and other pediatric rheu- matoid and nonrheumatic disorders. Rheum Dis Clin North Am 1997;23(4):811-40.
Job-Deslandre C, Menkes CJ. Administration of methylpred- nisolone pulse in chronic arthritis in children. Clin Exp Rheumatol 1991;9(Suppl 6):15-8.
Singer NG, McCune WJ. Update on immunosuppressive therapy. Curr Opin Rheumatol 1998;10(3):169-73.
Gaffney K, Scott DG. Azathioprine and cyclophosphamide in the treatment of rheumatoid arthritis. Br J Rheumatol 1998;37(8):824-36.
Ansell BM. Cyclosporin A in paediatric rheumatology. Clin Exp Rheumatol 1993;11(2):113-5.
Graham LD, Myones BL, Rivas-Chacon RF, Pachman LM. Morbidity associated with long-term methotrexate therapy in juvenile rheumatoid arthritis. J Pediatr 1992;120(3):468-73.
Wallace CA, Bleyer WA, Sherry DD, Salmonson KL, Wedg- wood RJ. Toxicity and serum levels of methotrexate in children with juvenile rheumatoid arthritis. Arthritis Rheum 1989;32(6):677-81.
Cron RQ, Sharma S, Sherry DD. Current treatment by United States and Canadian pediatric rheumatologists. J Rheumatol 1999;26(9):2036-8.
Wallace CA, Sherry DD. Trial of intravenous pulse cyclophos- phamide and methylprednisolone in the treatment of severe systemic-onset juvenile rheumatoid arthritis. Arthritis Rheum 1997;40(10):1852-5.
Shaikov AV, Maximov AA, Speransky AI, Lovell DJ, Giannini EH, Solovyev SK. Repetitive use of pulse therapy with methylpred- nisolone and cyclophosphamide in addition to oral methotrexate in children with systemic juvenile rheumatoid arthritis prelimi- nary results of a longterm study. J Rheumatol 1992;19(4):612-6.
